This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
New York-based Bristol-Myers Squibb is a one of the leading global specialty bio-pharmaceutical companies focused on the development of treatments targeting serious diseases. Backed by its blockbuster immune-oncology drug, Opdivo, Bristol-Myers has a strong oncology portfolio, consisting of other drugs like Revlimid, Sprycel, Yervoy and Empliciti. Beyond oncology, the company has important immunology and cardiovascular drugs like Orencia and Eliquis, which diversify its portfolio. Notably, in the cardiovascular space, Eliquis is now the global leading oral anti-coagulant drug. The company continues to experience growth in both the Eliquis brand and the market, while also advancing its Factor XIa inhibitor program..
Renal Cell Carcinoma Space in Focus: Some Key Developments
by Ekta Bagri
The first-line RCC treatment landscape is gradually changing. Let's take a look at the recent events in this space.
Roche Reports Positive Data on Tecentriq & NMOSD Drug (Revised)
by Zacks Equity Research
Roche's (RHHBY) immuno-oncology drug, Tecentriq, meets the primary goal in a late-stage study in NSCLC patients. Also, the company reports positive data on its NMOSD drug in a phase III study.
Horizon (HZNP) Up 36.7% YTD: Pipeline Development in Focus
by Zacks Equity Research
Shares of Horizon Therapeutics (HZNP) have gained year to date, owing to its focus on label expansions and pipeline development.
Zacks Market Edge Highlights: UnitedHealth, Centene, MasTec, Bank of America and Bristol-Myers Squibb
by Zacks Equity Research
Zacks Market Edge Highlights: UnitedHealth, Centene, MasTec, Bank of America and Bristol-Myers Squibb
Roche (RHHBY) Reports Positive Data on Tecentriq & MS Drug
by Zacks Equity Research
Roche's (RHHBY) immuno-oncology drug, Tecentriq, meets the primary goal in a late-stage study in NSCLC patients. Also, the company reports positive data on its MS drug in a phase III study.
Wall Street Bulls Roaring Despite Slowdown Fears: 5 Top Picks
by Nalak Das
Year to date, the performance on Wall Street is projecting a glorious picture with no end to the bull run in sight, at least this year.
Top Ranked Income Stocks to Buy for September 12th
by Zacks Equity Research
Here are four stocks with buy rank and strong income characteristics for investors to consider today, September 12th.
Bristol-Myers Squibb (BMY) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, Bristol-Myers Squibb (BMY) closed at $49.24, marking a +1.4% move from the previous day.
Could the Trade War be Bullish for Stocks?
by Tracey Ryniec
Tariffs, tweets, negotiations, the Fed cutting rates, full employment, a manufacturing slowdown: how investors can cut through the noise.
AVEO Surges on Favorable Updated OS Results on RCC Drug
by Zacks Equity Research
AVEO posts positive updated results from the second prespecified overall survival analysis of Fotivda for treating highly refractory metastatic renal cell carcinoma. Stock up more than 30%.
Bristol-Myers' (BMY) Opdivo Shows Long-Term Survival Benefit
by Zacks Equity Research
Bristol-Myers' (BMY) Opdivo continues to experience long-term OS benefit as demonstrated by the long-term pooled efficacy and safety results in patients with previously-treated NSCLC.
4 Big Drugmakers Boasting Impressive Oncology Pipelines
by Kinjel Shah
We discuss four pharma giants, which possess the industry's strongest oncology pipeline portfolios.
The Zacks Analyst Blog Highlights: Allergan, Merck, Roche, J&J and Bristol-Myers
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Allergan, Merck, Roche, J&J and Bristol-Myers
Why Bristol-Myers Squibb (BMY) is a Great Dividend Stock Right Now
by Zacks Equity Research
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Bristol-Myers Squibb (BMY) have what it takes? Let's find out.
Top Ranked Income Stocks to Buy for September 9th
by Zacks Equity Research
Here are four stocks with buy rank and strong income characteristics for investors to consider today, September 9th.
Pharma Stock Roundup: AGN's Opioid Settlement, Line Extension Nod in EU for MRK, JNJ Drugs
by Kinjel Shah
Allergan (AGN) settles with two Ohio plaintiffs for $5 million. Merck's (MRK) Keytruda, Roche's (RHHBY) Tecentriq and J&J's (JNJ) Stelara get EU approval for expanded use.
Bristol-Myers' (BMY) Opdivo Falls Flat in Brain Tumor Study
by Zacks Equity Research
Bristol-Myers (BMY) announces dismal results from a late-stage study on its immuno-oncology drug Opdivo for critical brain tumor.
Bristol-Myers Squibb (BMY) Gains But Lags Market: What You Should Know
by Zacks Equity Research
Bristol-Myers Squibb (BMY) closed at $48.51 in the latest trading session, marking a +0.81% move from the prior day.
Infinity Initiates 2 Studies for Lead Candidate IPI-549
by Zacks Equity Research
Infinity (INFI) initiates two studies for IPI-549 -- a first-in-class, oral immuno-oncology product candidate.
The Zacks Analyst Blog Highlights: Allegiant, Bristol-Myers, NewMarket, North American Construction and TiVo
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Allegiant, Bristol-Myers, NewMarket, North American Construction and TiVo
Roche Extends Offer to Acquire Spark Therapeutics Yet Again
by Zacks Equity Research
Roche's (RHHBY) acquisition of Spark Therapeutics gets delayed once again to allow the FTC more time for review.
5 Strong Buy Ultra-Safe Stocks for an Uncertain September
by Nalak Das
The lingering trade conflict between the United States and China is taking a toll on U.S. business activities, especially the manufacturing sector.
The Zacks Analyst Blog Highlights: TransDigm, Keysight, Bristol-Myers Squibb, NRG and Arconic
by Zacks Equity Research
The Zacks Analyst Blog Highlights: TransDigm, Keysight, Bristol-Myers Squibb, NRG and Arconic
Top-Performing Biotech ETFs YTD
by Sweta Jaiswal, FRM
Increasing M&A deals, growing AI dominance and favorable regulatory tidings continue to boost the biotech stocks. Accordingly, we take a look at biotech ETFs gaining more than 10% year to date.
The Zacks Analyst Blog Highlights: J&J, Eli Lilly, Bristol-Myers, Roche and AbbVie
by Zacks Equity Research
The Zacks Analyst Blog Highlights: J&J, Eli Lilly, Bristol-Myers, Roche and AbbVie